Private Label Three-Day Yeast Infection Cream Offered By Taro
This article was originally published in The Tan Sheet
Executive Summary
Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.
|
Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May. The yeast infection cream is the first product to appear under a joint research effort by Taro and Schering announced in April 1998 (1 (Also see "Taro Pharmaceuticals" - Pink Sheet, 15 Mar, 1999.)). The firms plan to introduce future vaginal yeast infection and other feminine hygiene products under their collaboration. Built into the agreement was a period of time allowing Schering to market Gyne-Lotrimin 3 with no generic competition. Schering launched the cream in February 1999; its NDA was approved in November 1998 (2 (Also see "Schering-Plough 2% Gyne-Lotrimin 3 Cream Will Be Launched In February" - Pink Sheet, 7 Dec, 1998.)). Taro is the first to offer a clotrimazole 2% cream for private label as a stand-alone product. Alpharma and Perrigo market private label three-day miconazole vaginal antifungal treatment combination packs equivalent to J&J's Monistat 3 Combination Pack. Private label products hold the largest dollar share of the overall feminine hygiene/medicinal treatments category, which includes yeast infection products in addition to such items as at-home pregnancy tests, feminine sprays, vaginal lubricants and anti-itch creams. In the 52-week period ending March 26, private label feminine hygiene/medicinal items captured a 17.1% dollar share ($139.1 mil.) of the $815.7 mil. market in food, drug and mass market outlets, according to Chicago-based Information Resources, Inc. Monistat 3 vaginal yeast infection product is the number one selling branded product in the broad category with a 9% dollar share ($73.2 mil.), IRI said. Gyne-Lotrimin does not appear among the top 15 feminine hygiene products listed by IRI. J&J's Monistat 7 is number six with a 5.8% share, followed by Monistat 1 with 4.5%. Bristol-Myers' Vagistat 1 is eighth with a 3% share and Bayer's Mycelex 3 Cream is fifteenth, holding a 2.2% share. |